EGFR and non-small cell lung carcinoma: Ph. Ib/Ph. II Group 1: advanced EGFR-mutant NSCLC progressing under G/E/APh. II Group 2: advanced NSCLC not been previously treated with any EGFR TKI and harbor de novo T790M mutation